Grothey Shares Encouraging Data from Lead-In Phase of BEACON CRC Trial
Axel Grothey, MD, discusses the results from the safety lead-in phase of the BEACON CRC trial investigating the triplet regimen of BRAF inhibitor encorafenib, MEK inhibitor binimetinib, and anti-EGFR antibody cetuximab in patients with <em>BRAF</em>V600E-mutant metastatic colorectal cancer.
Axel Grothey, MD, medical oncologist at West Cancer Center, discusses the results from the safety lead-in phase of the BEACON CRC trial investigating the triplet regimen of BRAF inhibitor encorafenib (Braftovi), MEK inhibitor binimetinib (Mektovi), and anti-EGFR antibody cetuximab (Erbitux) in patients withBRAFV600E-mutant metastatic colorectal cancer (mCRC).
Out of the 30 patients available for the safety analysis, 29 were available for efficacy. There was a response rate of 48% among these patients. Also, not one patient had progression of disease by RECIST criteria in this analysis.
The median progression-free survival is 8 months in this patient population, which far exceeds historical controls of about 2 to 4 months. Additionally, the median overall survival is 15.3 months, which is almost 3 times as long as current standards of care. Grothey notes that this is much longer than seen with other biologic combinations in this setting.
See more from the 2019 Gastrointestinal Cancers Symposium.
Retrospective Data Demonstrates Efficacy of Regorafenib in mCRC
April 16th 2024During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that compared outcomes between the available treatment options in patients with relapsed/refractory advanced colorectal cancer in the first article of a 2-part series.
Read More
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
